Market Research Reports and Industry Reports

Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29% between 2015 and 2020. By product, the market includes software and services. Based on application, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. Preclinical testing includes ADME/Tox and PK/PD applications. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment is expected to grow at the highest rate.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in the global biosimulation market in 2015. Europe is expected to register the fastest growth.

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Other growth factors include the need to curtail drug discovery & development costs, technological advancements, growth in the biologics and biosimilars markets, and the increased use of personalized medicines.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global biosimulation market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates. The report provides qualitative insights about growth rates, and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic segment. The report also includes company profiles of market leaders.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

Product Development: Product portfolios of the top players in the biosimulation market.
Competitive Assessment: In-depth assessment of the business segments and product portfolios of the leading players in the biosimulation market.
Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biosimulation products and services across geographies.
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.2.1 MARKETS COVERED 16
1.2.2 YEARS CONSIDERED FOR THE STUDY 16
1.3 CURRENCY 17
1.4 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 29
4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOSIMULATION MARKET 29
4.2 LIFE CYCLE ANALYSIS, BY REGION (20152020) 30
5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.2 MARKET SEGMENTATION 33
5.2.1 BY PRODUCT 33
5.2.2 BY APPLICATION 34
5.2.3 BY END USER 34
5.3 MARKET DYNAMICS 35
5.3.1 DRIVERS 36
5.3.1.1 Growth in the pharmaceutical and biotechnology industries 36
5.3.1.2 Increase in R&D investments in the pharmaceutical and biotechnology industries 36
5.3.1.3 Technological advancements 37
5.3.1.4 Need to curtail drug discovery and development costs 37
5.3.1.5 Growth in the biologics and biosimilars market and increased use of personalized medicines 37
5.3.2 RESTRAINTS 39
5.3.2.1 Lack of standardization 39
5.3.2.2 Lack of trained professionals 39
5.3.3 OPPORTUNITIES 40
5.3.3.1 Emerging applications 40
5.3.4 CHALLENGES 41
5.3.4.1 Limited knowledge of biological systems and processes 41
5.3.5 TRENDS 42
5.3.5.1 Collaborations of universities and research labs with suppliers 42
6 BIOSIMULATION MARKET, BY PRODUCT 43
6.1 INTRODUCTION 44
6.2 SOFTWARE 46
6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE 48
6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE 49
6.2.3 PBPK MODELING AND SIMULATION SOFTWARE 50
6.2.4 TOXICITY PREDICTION SOFTWARE 50
6.2.5 TRIAL DESIGN SOFTWARE 51
6.2.6 OTHER SOFTWARE 52
6.3 SERVICES 53
6.3.1 IN-HOUSE SERVICES 55
6.3.2 EXTERNAL/CONTRACT SERVICES 55
7 BIOSIMULATION MARKET, BY APPLICATION 57
7.1 INTRODUCTION 58
7.2 DRUG DEVELOPMENT 59
7.2.1 PRECLINICAL TESTING 62
7.2.1.1 PK/PD 64
7.2.1.2 ADME/Tox 65
7.2.2 CLINICAL TRIALS 66
7.3 DRUG DISCOVERY 66
7.3.1 TARGET IDENTIFICATION AND VALIDATION 69
7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION 70
7.4 OTHER APPLICATIONS 71
8 BIOSIMULATION MARKET, BY END USER 73
8.1 INTRODUCTION 74
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 76
8.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 78
8.4 CONTRACT RESEARCH ORGANIZATIONS 80
8.5 REGULATORY AUTHORITIES 81
8.6 OTHER END USERS 83
9 GLOBAL BIOSIMULATION MARKET, BY REGION 85
9.1 INTRODUCTION 86
9.2 NORTH AMERICA 88
9.3 EUROPE 95
9.4 ASIA 101
9.5 REST OF THE WORLD (ROW) 107
10 COMPETITIVE LANDSCAPE 113
10.1 INTRODUCTION 113
10.2 STRATEGIC OVERVIEW 113
10.3 LEADING PLAYERS IN THE BIOSIMULATION MARKET 114
10.4 COMPETITIVE SITUATION AND TRENDS 115
10.4.1 PRODUCT UPGRADATION 115
10.4.2 AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS 116
10.4.3 NEW PRODUCT AND SERVICE LAUNCHES 117
10.4.4 ACQUISITIONS 118
10.4.5 OTHER DEVELOPMENTS 118
11 COMPANY PROFILES 120
11.1 INTRODUCTION 120
11.2 CERTARA USA, INC. 121
11.3 SIMULATION PLUS INC. 123
11.4 DASSAULT SYSTMES SA 125
11.5 SCHRDINGER INC. 127
11.6 ADVANCED CHEMISTRY DEVELOPMENT, INC. 129
11.7 CHEMICAL COMPUTING GROUP, INC. 131
11.8 ENTELOS HOLDING CORPORATION 132
11.9 GENEDATA AG 133
11.10 PHYSIOMICS PLC 134
11.11 RHENOVIA PHARMA LTD. 136
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
12 APPENDIX 137
12.1 INSIGHTS OF INDUSTRY EXPERTS 137
12.2 DISCUSSION GUIDE 138
12.3 OTHER DEVELOPMENTS 141
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 146
12.5 AVAILABLE CUSTOMIZATIONS 147
12.6 RELATED REPORTS 148

List Of Tables

TABLE 1 BIOSIMULATION MARKET SUMMARY 25
TABLE 2 GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES ALONG WITH INCREASE IN R&D INVESTMENTS IN THESE INDUSTRIES IS PROPELLING THE GROWTH OF THE BIOSIMULATION MARKET 38
TABLE 3 LACK OF STANDARDIZATION TO RESTRICT MARKET GROWTH 40
TABLE 4 EMERGING APPLICATIONS PRESENT SIGNIFICANT GROWTH OPPORTUNITIES FOR THE BIOSIMULATION MARKET 41
TABLE 5 LIMITED KNOWLEDGE OF BIOLOGICAL SYSTEMS AND PROCESSES POSE A CHALLENGE FOR THE BIOSIMULATION MARKET 41
TABLE 6 COLLABORATIONS OF UNIVERSITIES AND RESEARCH LABS WITH SUPPLIERS IS A MAJOR TREND OBSERVED IN THIS MARKET 42
TABLE 7 BIOSIMULATION MARKET SIZE, BY PRODUCT, 20132020 (USD MILLION) 45
TABLE 8 BIOSIMULATION SOFTWARE MARKET SIZE, BY TYPE, 20132020 (USD MILLION) 47
TABLE 9 BIOSIMULATION SOFTWARE MARKET SIZE, BY REGION, 20132020 (USD MILLION) 48
TABLE 10 BIOSIMULATION MARKET SIZE FOR PK/PD MODELING AND SIMULATION SOFTWARE, BY REGION, 20132020 (USD MILLION) 48
TABLE 11 BIOSIMULATION MARKET SIZE FOR MOLECULAR MODELING AND SIMULATION SOFTWARE, BY REGION, 20132020 (USD MILLION 49
TABLE 12 BIOSIMULATION MARKET SIZE FOR PBPK MODELING AND SIMULATION SOFTWARE, BY REGION, 20132020 (USD MILLION) 50
TABLE 13 BIOSIMULATION MARKET SIZE FOR TOXICITY PREDICTION SOFTWARE, BY REGION, 20132020 (USD MILLION) 51
TABLE 14 BIOSIMULATION MARKET SIZE FOR TRIAL DESIGN SOFTWARE, BY REGION,
20132020 (USD MILLION) 51
TABLE 15 BIOSIMULATION MARKET SIZE FOR OTHER SOFTWARE, BY REGION,
20132020 (USD MILLION) 52
TABLE 16 BIOSIMULATION SERVICES MARKET SIZE, BY TYPE, 20132020 (USD MILLION) 53
TABLE 17 BIOSIMULATION SERVICES MARKET SIZE, BY REGION, 20132020 (USD MILLION) 54
TABLE 18 BIOSIMULATION MARKET SIZE FOR IN-HOUSE SERVICES, BY REGION,
20132020 (USD MILLION) 55
TABLE 19 BIOSIMULATION MARKET SIZE FOR EXTERNAL/CONTRACT SERVICES
, BY REGION, 20132020 (USD MILLION) 56
TABLE 20 BIOSIMULATION MARKET SIZE, BY APPLICATION, 20132020 (USD MILLION) 59
TABLE 21 BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY APPLICATION, 20132020 (USD MILLION ) 60
TABLE 22 BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY REGION,
20132020 (USD MILLION) 61
TABLE 23 BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY APPLICATION, 20132020 (USD MILLION ) 62
TABLE 24 BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY REGION,
20132020 (USD MILLION ) 63
TABLE 25 BIOSIMULATION MARKET SIZE FOR PK/PD, BY REGION,
20132020 (USD MILLION) 64
TABLE 26 BIOSIMULATION MARKET SIZE FOR ADME/TOX, BY REGION,
20132020 (USD MILLION) 65
TABLE 27 BIOSIMULATION MARKET SIZE FOR CLINICAL TRIALS, BY REGION,
20132020 (USD MILLION) 66
TABLE 28 BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY APPLICATION,
20132020 (USD MILLION ) 67
TABLE 29 BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY REGION,
20132020 (USD MILLION ) 68
TABLE 30 BIOSIMULATION MARKET SIZE FOR TARGET IDENTIFICATION AND OPTIMIZATION, BY REGION, 20132020 (USD MILLION) 69
TABLE 31 BIOSIMULATION MARKET SIZE FOR LEAD IDENTIFICATION AND OPTIMIZATION,
BY REGION, 20132020 (USD MILLION) 70
TABLE 32 BIOSIMULATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION,
20132020 (USD MILLION ) 72
TABLE 33 BIOSIMULATION MARKET SIZE, BY END USER, 20132020 (USD MILLION) 75
TABLE 34 BIOSIMULATION MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 20132020 (USD MILLION) 77
TABLE 35 BIOSIMULATION MARKET SIZE FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 20132020 (USD MILLION) 79
TABLE 36 BIOSIMULATION MARKET SIZE FOR CROS, BY REGION, 20132020 (USD MILLION) 81
TABLE 37 BIOSIMULATION MARKET SIZE FOR REGULATORY AUTHORITIES, BY REGION, 20132020 (USD MILLION) 82
TABLE 38 BIOSIMULATION MARKET SIZE FOR OTHER END USERS, BY REGION,
20132020 (USD MILLION) 84
TABLE 39 BIOSIMULATION MARKET SIZE, BY REGION, 20132020 (USD MILLION) 87
TABLE 40 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY PRODUCT,
20132020 (USD MILLION) 90
TABLE 41 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY SOFTWARE,
20132020 (USD MILLION) 91
TABLE 42 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY SERVICE,
20132020 (USD MILLION) 91
TABLE 43 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY APPLICATION,
20132020 (USD MILLION) 92
TABLE 44 NORTH AMERICA: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 20132020 (USD MILLION) 93
TABLE 45 NORTH AMERICA: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 20132020 (USD MILLION) 93
TABLE 46 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY END USER,
20132020 (USD MILLION) 94
TABLE 47 EUROPE: BIOSIMULATION MARKET SIZE, BY PRODUCT, 20132020 (USD MILLION) 97
TABLE 48 EUROPE: BIOSIMULATION MARKET SIZE, BY SOFTWARE,
20132020 (USD MILLION) 98
TABLE 49 EUROPE: BIOSIMULATION MARKET SIZE, BY SERVICE, 20132020 (USD MILLION) 98
TABLE 50 EUROPE: BIOSIMULATION MARKET SIZE, BY APPLICATION,
20132020 (USD MILLION) 99
TABLE 51 EUROPE: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 20132020 (USD MILLION) 99
TABLE 52 EUROPE: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 20132020 (USD MILLION) 100
TABLE 53 EUROPE: BIOSIMULATION MARKET SIZE, BY END USER,
20132020 (USD MILLION) 101
TABLE 54 ASIA: BIOSIMULATION MARKET SIZE, BY PRODUCT, 20132020 (USD MILLION) 102
TABLE 55 ASIA: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 20132020 (USD MILLION) 103
TABLE 56 ASIA: BIOSIMULATION MARKET SIZE, BY SERVICE, 20132020 (USD MILLION) 103
TABLE 57 ASIA: BIOSIMULATION MARKET SIZE, BY APPLICATION, 20132020 (USD MILLION) 104
TABLE 58 ASIA: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 20132020 (USD MILLION) 105
TABLE 59 ASIA: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 20132020 (USD MILLION) 105
TABLE 60 ASIA: BIOSIMULATION MARKET SIZE, BY END USER, 20132020 (USD MILLION) 106
TABLE 61 ROW: BIOSIMULATION MARKET SIZE, BY PRODUCT, 20132020 (USD MILLION) 108
TABLE 62 ROW: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 20132020 (USD MILLION) 109
TABLE 63 ROW: BIOSIMULATION MARKET SIZE, BY SERVICE, 20132020 (USD MILLION) 109
TABLE 64 ROW: BIOSIMULATION MARKET SIZE, BY APPLICATION, 20132020 (USD MILLION) 110
TABLE 65 ROW: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 20132020 (USD MILLION) 111
TABLE 66 ROW: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 20132020 (USD MILLION) 111
TABLE 67 ROW: BIOSIMULATION MARKET SIZE, BY END USER, 20132020 (USD MILLION) 112
TABLE 68 RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2015 114
TABLE 69 MARKET DEVELOPMENTS BETWEEN 20132015 115
TABLE 70 PRODUCT UPGRADATION, 20132015 116
TABLE 71 AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS,
20132015 116
TABLE 72 NEW PRODUCT AND SERVICE LAUNCHES, 20132015 117
TABLE 73 ACQUISITIONS, 20132015 118
TABLE 74 OTHER DEVELOPMENTS, 20132015 119

List Of Figures

FIGURE 1 GLOBAL BIOSIMULATION MARKET 16
FIGURE 2 RESEARCH DESIGN 18
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 21
FIGURE 6 DATA TRIANGULATION METHODOLOGY 22
FIGURE 7 BIOSIMULATION MARKET SIZE, BY PRODUCT, 2015 VS. 2020 (USD MILLION) 26
FIGURE 8 BIOSIMULATION MARKET SIZE, BY APPLICATION, 2015 VS. 2020 (USD MILLION) 26
FIGURE 9 BIOSIMULATION MARKET SIZE, BY END USER, 2015 VS. 2020 (USD MILLION) 27
FIGURE 10 BIOSIMULATION MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION) 28
FIGURE 11 GLOBAL BIOSIMULATION MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 29
FIGURE 12 SOFTWARE PRODUCT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015 29
FIGURE 13 EUROPE TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020 30
FIGURE 14 EUROPEAN MARKET SHOWCASES LUCRATIVE GROWTH OPPORTUNITIES 30
FIGURE 15 BIOSIMULATION MARKET SEGMENTATION: BY PRODUCT 33
FIGURE 16 BIOSIMULATION MARKET SEGMENTATION: BY APPLICATION 34
FIGURE 17 BIOSIMULATION MARKET SEGMENTATION: BY END USER 34
FIGURE 18 GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES ALONG WITH INCREASE IN R&D INVESTMENTS IN THESE INDUSTRIES WILL DRIVE THE BIOSIMULATION MARKET 35
FIGURE 19 NEW PHARMACEUTICAL DRUG LAUNCHES (20032013) 36
FIGURE 20 BIOSIMULATION MARKET SEGMENTATION, BY PRODUCT 44
FIGURE 21 BIOSIMULATION MARKET, BY PRODUCT, 2015 (USD MILLION) 45
FIGURE 22 BIOSIMULATION SOFTWARE MARKET SIZE, BY TYPE, 2015 VS. 2020 (USD MILLION) 46
FIGURE 23 BIOSIMULATION SOFTWARE MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION) 47
FIGURE 24 BIOSIMULATION SERVICES MARKET SIZE, BY TYPE, 20132020 (USD MILLION) 53
FIGURE 25 BIOSIMULATION SERVICES MARKET SIZE, BY REGION, 20132020 (USD MILLION) 54
FIGURE 26 BIOSIMULATION MARKET SEGMENTATION, BY APPLICATION 58
FIGURE 27 DRUG DEVELOPMENT SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN 2015 58
FIGURE 28 BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY APPLICATION,
2015 VS. 2020 (USD MILLION ) 60
FIGURE 29 NORTH AMERICA EXPECTED TO BE THE LARGEST REGIONAL SEGMENT FOR DRUG DEVELOPMENT APPLICATIONS 61
FIGURE 30 BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY APPLICATION,
2015 VS. 2020 (USD MILLION) 62
FIGURE 31 NORTH AMERICA EXPECTED TO BE THE LARGEST REGIONAL SEGMENT FOR PRECLINICAL TESTING APPLICATIONS 63
FIGURE 32 BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY APPLICATION, 2015 VS. 2020 (USD MILLION ) 67
FIGURE 33 EUROPE IS THE FASTEST-GROWING REGIONAL SEGMENT FOR DRUG DISCOVERY APPLICATIONS 68
FIGURE 34 OTHER APPLICATIONS MARKET IN EUROPE TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD 71
FIGURE 35 BIOSIMULATION MARKET, BY END USER 74
FIGURE 36 BIOSIMULATION MARKET SIZE, BY END USER, 2015 (USD MILLION) 74
FIGURE 37 NUMBER OF BIOTECHNOLOGY AND PHARMACEUTICAL PATENTS GRANTED IN 2012, BY REGION 76
FIGURE 38 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT TO WITNESS HIGHEST GROWTH IN EUROPE 77
FIGURE 39 PUBLIC-SECTOR RESEARCH FUNDING DRIVING THE GROWTH OF THE ACADEMIC & GOVERNMENT RESEARCH INSTITUTES END-USER SEGMENT 78
FIGURE 40 NORTH AMERICA DOMINATES MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 79
FIGURE 41 NORTH AMERICA EXPECTED TO DOMINATE BIOSIMULATION MARKET FOR CROS 80
FIGURE 42 EUROPE IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES 82
FIGURE 43 EUROPE TO WITNESS HIGHEST GROWTH IN THE BIOSIMULATION MARKET FOR OTHER END USERS IN THE FORECAST PERIOD 83
FIGURE 44 BIOSIMULATION MARKET SEGMENTATION, BY REGION 86
FIGURE 45 NORTH AMERICA TO DOMINATE THE GLOBAL BIOSIMULATION MARKET IN THE FORECAST PERIOD 86
FIGURE 46 BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH FROM 2015 TO 2020 87
FIGURE 47 NORTH AMERICA: MARKET SNAPSHOT 89
FIGURE 48 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN NORTH AMERICA IN 2015 90
FIGURE 49 DRUG DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION APPLICATIONS MARKET IN NORTH AMERICA BY 2020 92
FIGURE 50 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO FORM THE LARGEST END-USER SEGMENT IN NORTH AMERICA IN 2015 94
FIGURE 51 EUROPE: MARKET SNAPSHOT 96
FIGURE 52 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE EUROPEAN BIOSIMULATION MARKET IN 2015 97
FIGURE 53 DRUG DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION APPLICATIONS MARKET IN EUROPE BY 2020 99
FIGURE 54 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION END-USER MARKET IN EUROPE IN 2015 100
FIGURE 55 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN ASIA IN 2015 102
FIGURE 56 DRUG DEVELOPMENT APPLICATION SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN ASIA BY 2020 104
FIGURE 57 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION END-USER MARKET IN ASIA IN 2015 106
FIGURE 58 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE ROW BIOSIMULATION MARKET IN 2015 108
FIGURE 59 DRUG DEVELOPMENT APPLICATION SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN THE ROW REGION BY 2020 110
FIGURE 60 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES END-USER SEGMENT TO DOMINATE THE ROW MARKET FOR BIOSIMULATION IN 2015 112
FIGURE 61 KEY DEVELOPMENTS IN THE BIOSIMULATION MARKET, 2013-2015 113
FIGURE 62 GEOGRAPHICAL MIX OF THE TOP 4 MARKET PLAYERS 120
FIGURE 63 COMPANY SNAPSHOT: SIMULATION PLUS INC. 123
FIGURE 64 COMPANY SNAPSHOT: DASSAULT SYSTMES SA 125
FIGURE 65 COMPANY SNAPSHOT: PHYSIOMICS PLC 134

Global Biosimulation Market Report 2016

2016 Global Biosimulation Report is a professional and in-depth research report on the worlds major regional market conditions of the Biosimulation industry, focusing on the main regions (North America, Europe

USD 2850View Report

United States Biosimulation Technology Industry 2016 Market Research Report

The United States Biosimulation Technology Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Biosimulation Technology industry.The report provides a basic overview

USD 3800View Report

Global Biosimulation Industry 2016 Market Research Report

The Global Biosimulation Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Biosimulation industry.Firstly, the report provides a basic overview of the

USD 2800View Report

Syringes Market by Usability - Global Forecast to 2021

Syringes Market by Usability (Sterilizable/reusable (hypodermic, oral) & Disposable Syringes (conventional, safety, prefilled)), Material (Glass & Plastic Syringes), Type (General & Specialized Syringes (insulin, tuberculin) - Global Forecast to 2021

USD 5650View Report

GFRP Composites Market By Resin Type - Global Forecast To 2026

GFRP Composites Market By Resin Type (Polyester, Vinyl Ester, Epoxy, Polyurethane), Manufacturing Process (Manual Process, Compression Molding, Continuous Process, Injection Molding), Application (Wind Energy, Transportation, Marine, Pipe & Tanks) By

USD 5650View Report

India Television Market By Type (LED, OLED, LCD, Plasma), By Resolution (High Definition (HD, Full High Definition (FHD) and Ultra-High Definition (UHD)), Forecast & Opportunities, 2021

From luxury to necessity, television has now become an integral part of the daily life. Over the period of time, the countrys television market has seen numerous technological advancements

USD 2500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 4650
  • Multi User Licence    $ 5650
  • Corporate Licence    $ 7150
  • Enterprise Wide Licence    $ 9000
$ 4650

Reports Details

Published Date : Jul 2015
No. of Pages :149
Country :Global
Category :Healthcare
Publisher :MarketsandMarkets
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment